These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10754421)

  • 1. Morbidity and mortality reduction associated with the use of erythropoietin.
    Tsakiris D
    Nephron; 2000; 85 Suppl 1():2-8. PubMed ID: 10754421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical relevance of anemia treatment in patients with chronic kidney disease].
    Vuksanović-Mikulicić S; Mikolasević I; Jelić I; Bubić I; Sladoje-Martinović B; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):193-202. PubMed ID: 23441533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry.
    Locatelli F; Conte F; Marcelli D
    Nephrol Dial Transplant; 1998 Jul; 13(7):1642-4. PubMed ID: 9681705
    [No Abstract]   [Full Text] [Related]  

  • 7. Defining a renal anemia management period.
    Besarab A; Levin A
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S13-23. PubMed ID: 11118154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of renal anemia with erythropoietin].
    Spustova V; Kovac A
    Bratisl Lek Listy; 1999 Aug; 100(8):432-8. PubMed ID: 10645031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study.
    Möcks J
    Nephron; 2000 Dec; 86(4):455-62. PubMed ID: 11124594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin treatment in anaemic patients on haemodialysis.
    Zins B; Drüeke T; Zingraff J; Bererhi L; Kreis H; Naret C; Delons S; Castaigne JP; Peterlongo F; Casadevall N
    Lancet; 1986 Dec; 2(8519):1329. PubMed ID: 2878188
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic kidney failure, anemia and erythropoietin].
    Sulková S
    Cas Lek Cesk; 1990 May; 129(18):545-9. PubMed ID: 2350772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
    Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
    Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
    Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaemia of chronic kidney disease: an under-recognized and under-treated problem.
    Obrador GT; Pereira BJ
    Nephrol Dial Transplant; 2002; 17 Suppl 11():44-6. PubMed ID: 12386258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment.
    Cetinkaya R; Odabas AR; Selcuk Y; Erman Z; Kaya H
    South Med J; 2003 May; 96(5):491-3. PubMed ID: 12911189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.